Top 30 401(k) Plans of 2012
Brightscope, which provides retirement plan ratings and investment research, released its fourth annual Top 30 401(k) plans with more than $1 billion in assets.
New drug developments, partnerships and clinical-trial results could propel the sector this year, analysts say. --- Larry NeiborRobert W. Baird & Co. firstname.lastname@example.org Area of coverage: Specialty Pharmaceuticals Sector...
Fund in Focus: Constellation Sands Capital Select Growth
Frank Sands Jr., manager since July 2000 S&P Rank: 3 Stars Bulking Up On Biotech
Evan McCulloch of Franklin Biotechnology Discovery Fund
S&P Rank: 3 Stars March 11, 2004 Biotechs High on Drug Approvals
Liu-Er Chen of Evergreen Health Care Fund
S&P Rank: 4 Stars Aug. 14, 2003 On the Cusp of a New Drug Boom Quick Take: Drug and biotech stocks suffered in 2002, hurt by poor earnings,...
Domestic Equity Funds -- July 2003 Review
'Rising Tide Lifts All Boats'